TrialReader


Measuring Geographic Atrophy in AMD Patients Using the Nidek MP-3 Microperimetry Device

NCT02445313 — Completed, 100 participants, Doheny Image Reading Center

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  
RegistryNCT02445313
StatusCompleted
Study typeObservational
Enrollment100 (Actual)
SponsorDoheny Image Reading Center (Other)
ConditionsAge-related Macular Degeneration (AMD)
InterventionsNidek MP-3 (Device)
Datesstart 2015-06-01, primary completion 2019-02-12, completion 2019-02-12, first posted 2015-05-15, last updated 2019-02-15
Locations1 site in United States

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Age-related Macular Degeneration (AMD) All trials of Nidek MP-3

-Summary

The investigators would like to know if different imaging devices can improve the quality of images and visualization of imaged tissues. Also, the investigators would like to find out whether these changes are useful in the diagnosis and treatment of eye diseases. Using images of previous participants will allow us to demonstrate the advancement of different technologies, as well be used to allow comparisons between current technologies.

Expand all sections  ·  Collapse all

+Detailed description

To test the quality of images from the Nidek MP-3 device and to measure Geographic Atrophy (GA) in patients with Age-related Macular Degeneration (AMD).

+Arms and interventions

ArmTypeInterventionsDescription
ControlDevice: Nidek MP-3Normal, healthy participants
AMDDevice: Nidek MP-3Age-related Macular Degeneration participants
  • Nidek MP-3 (Device): Nidek MP-3 device to be used to take images which will allow measurement of GA in patients with AMD

+Outcome measures

Primary outcomes

  • Geographic Atrophy [1 year]

+Eligibility

Sex: All, accepts healthy volunteers

Inclusion Criteria:

* Normal, healthy participants and patients with AMD

Exclusion Criteria:

1. Those suffering from head, neck or other injury which makes them unable to position themselves in head restraint for imaging
2. Participants who are unable to maintain retinal fixation on a specified target
3. Participants unable to achieve sufficient pupil dilation and alignment stability for imaging to take place
4. Patients with media opacity which preclude high quality imaging will be excluded.
5. Exclusion criteria include vulnerable patients; patients under 18, pregnant, economically and educationally disadvantaged, decision impaired, or homeless people. We exclude pregnant women because pregnancy often can alter eye anatomy.

+Locations (1)

FacilityCityCountryStatus
Doheny Eye Centers UCLAPasadena, CaliforniaUnited States

+Investigators

My Notes